Nocturnal systemic hypotension increases the risk of glaucoma progression

Charlson ME, de Moraes CG, Link A, Wells MT, Harmon G, Peterson JC, Ritch R, Liebmann JM

1 Center for Integrative Medicine, Weill Cornell Medical College, New York, New York. Electronic address: mecharl@med.cornell.edu.
2 Einhorn Clinical Research Center, New York Eye and Ear Infirmary at Mount Sinai School of Medicine, New York, New York; Department of Ophthalmology, New York University Medical Center, New York, New York.
3 Center for Integrative Medicine, Weill Cornell Medical College, New York, New York.
4 Department of Statistical Science, Cornell University, Ithaca, New York.
5 Department of Ophthalmology, Weill Cornell Medical College, New York, New York.
6 Einhorn Clinical Research Center, New York Eye and Ear Infirmary at Mount Sinai School of Medicine, New York, New York.

OBJECTIVE: The objective of this prospective, longitudinal study of patients with normal-tension glaucoma (NTG) was to determine whether patients with nocturnal hypotension are at greater risk for visual field (VF) loss over 12 months than those without nocturnal hypotension.

DESIGN: Prospective, longitudinal study.

PARTICIPANTS: Consecutive patients with NTG with at least 5 prior VF tests were screened for eligibility.

METHODS: The baseline evaluation assessed demographic and clinical characteristics, covering systemic comorbid conditions, including systemic hypertension. All oral and ophthalmologic medications were recorded. A complete ophthalmological examination was performed at baseline and follow-up. Patients had their blood pressure (BP) monitored every 30 minutes for 48 hours with an ambulatory recording device at baseline and 6 and 12 months.

MAIN OUTCOME MEASURES: The primary outcome was based on the global rates of VF progression by linear regression of the mean VF threshold sensitivity over time (decibels/year).

RESULTS: Eighty-five patients with NTG (166 eyes; mean age, 65 years; 67% were women) were included. Of the 85 patients, 29% had progressed in the 5 VFs collected before study enrollment. The nocturnal mean arterial pressure (MAP) was compared with the daytime MAP. Multivariate analysis showed that the total time that sleep MAP was 10 mmHg below the daytime MAP was a significant predictor of subsequent VF progression. Conclusions: Cumulative nocturnal hypotension predicted VF loss in this cohort. Our data suggest that the duration and magnitude of decrease in nocturnal blood pressure below the daytime MAP, especially pressures that are 10 mmHg lower than daytime MAP, predict progression of NTG. Low nocturnal blood pressure, whether occurring spontaneously or as a result of medications, may lead to worsening of VF defects.

Copyright © 2014 American Academy of Ophthalmology.